Literature DB >> 35298594

Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.

Jan Philipp Bewersdorf1,2,3, Kishan K Patel1,2, George Goshua1,4, Rory M Shallis1,2, Nikolai A Podoltsev1,2, Scott F Huntington1,2, Amer M Zeidan1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35298594      PMCID： PMC8931513          DOI： 10.1182/blood.2021014401

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  17 in total

1.  Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.

Authors:  Jill A Bell; Aaron Galaznik; Eileen Farrelly; Marlo Blazer; Sharanya Murty; Augustina Ogbonnaya; Michael Eaddy; Robert J Fram; Douglas V Faller; Vamsi Kota
Journal:  Leuk Res       Date:  2018-06-18       Impact factor: 3.156

2.  Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.

Authors:  Edmond Chiche; Ramy Rahmé; Sarah Bertoli; Pierre-Yves Dumas; Jean-Baptiste Micol; Yosr Hicheri; Florence Pasquier; Pierre Peterlin; Patrice Chevallier; Xavier Thomas; Michael Loschi; Alexis Genthon; Ollivier Legrand; Mohamad Mohty; Emmanuel Raffoux; Patrick Auberger; Alexis Caulier; Magalie Joris; Caroline Bonmati; Gabrielle Roth-Guepin; Caroline Lejeune; Arnaud Pigneux; Norbert Vey; Christian Recher; Lionel Ades; Thomas Cluzeau
Journal:  Blood Adv       Date:  2021-01-12

3.  Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse.

Authors:  William Irish; Michael Ryan; Larry Gache; Candace Gunnarsson; Timothy Bell; Mark Shapiro
Journal:  Curr Med Res Opin       Date:  2016-12-14       Impact factor: 2.580

4.  Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.

Authors:  Kathleen F Villa; Robert J Ryan; Michael Chiarella; Arthur C Louie
Journal:  J Med Econ       Date:  2020-04-10       Impact factor: 2.448

Review 5.  Economic burden associated with acute myeloid leukemia treatment.

Authors:  Amer M Zeidan; Dalia Mahmoud; Izabela T Kucmin-Bemelmans; Cathelijne J M Alleman; Marja Hensen; Barry Skikne; B Douglas Smith
Journal:  Expert Rev Hematol       Date:  2015-11-14       Impact factor: 2.929

6.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

Authors:  Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats
Journal:  JAMA       Date:  2016-09-13       Impact factor: 56.272

7.  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Authors:  Jeffrey E Lancet; Geoffrey L Uy; Jorge E Cortes; Laura F Newell; Tara L Lin; Ellen K Ritchie; Robert K Stuart; Stephen A Strickland; Donna Hogge; Scott R Solomon; Richard M Stone; Dale L Bixby; Jonathan E Kolitz; Gary J Schiller; Matthew J Wieduwilt; Daniel H Ryan; Antje Hoering; Kamalika Banerjee; Michael Chiarella; Arthur C Louie; Bruno C Medeiros
Journal:  J Clin Oncol       Date:  2018-07-19       Impact factor: 44.544

8.  Systematic review of health state utility values for acute myeloid leukemia.

Authors:  Anna Forsythe; Patricia S Brandt; Mike Dolph; Sachin Patel; Adrian Paul J Rabe; Gabriel Tremblay
Journal:  Clinicoecon Outcomes Res       Date:  2018-01-25

9.  CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.

Authors:  Fabio Guolo; Luana Fianchi; Paola Minetto; Marino Clavio; Michele Gottardi; Sara Galimberti; Giuliana Rizzuto; Michela Rondoni; Giambattista Bertani; Michela Dargenio; Atto Bilio; Barbara Scappini; Patrizia Zappasodi; Anna Maria Scattolin; Francesco Grimaldi; Giuseppe Pietrantuono; Pellegrino Musto; Marco Cerrano; Stefano D'Ardia; Ernesta Audisio; Alessandro Cignetti; Crescenza Pasciolla; Francesca Pavesi; Anna Candoni; Carmela Gurreri; Monica Morselli; Caterina Alati; Nicola Fracchiolla; Giovanni Rossi; Manuela Caizzi; Fabrizio Carnevale-Schianca; Agostino Tafuri; Giuseppe Rossi; Felicetto Ferrara; Livio Pagano; Roberto Massimo Lemoli
Journal:  Blood Cancer J       Date:  2020-10-06       Impact factor: 11.037

10.  Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia.

Authors:  Jan Philipp Bewersdorf; Kishan K Patel; Scott F Huntington; Amer M Zeidan
Journal:  Blood Adv       Date:  2021-11-23
View more
  1 in total

1.  Nanoengineered, magnetically guided drug delivery for tumors: A developmental study.

Authors:  Tieyu Chen; Yanyu Kou; Ruiling Zheng; Hailun Wang; Gang Liang
Journal:  Front Chem       Date:  2022-10-04       Impact factor: 5.545
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.